A&P senior director of pharmacy promoted
MONTVALE, N.J. A&P has promoted Carol DiNicolantonio to VP pharmacy.
Previously, DiNicolantonio was the senior director of pharmacy. In that role she supervised 20 direct reports and more than 800 pharmacists. She was also responsible for more than $500 million in annual sales for 247 pharmacies spanning six states. She directed all aspects of pharmacy operations, marketing, merchandising and health and wellness programs for the company.
DiNicolantonio’s promotion to VP, added a spokesperson, comes “in recognition and appreciation of her performance and leadership in her respective business unit. Carol… did not replace anyone in the position,” the spokesperson told Drug Store News.
In addition, she developed and implemented the company’s Live Better! Wellness Program, which provides discounts on OTC items and a wide range of grocery products that promote a healthy lifestyle.
Hy-Vee celebrates the other white meat
WEST DES MOINES, Iowa A lot of people complain about pork barrel spending, but not Midwest supermarket chain Hy-Vee.
October is National Pork Month, and the West Des Moines, Iowa-based Hy-Vee announced Friday that sales of the meat have increased more than 25% over October 2008. The chain said it was on track to increase pork tonnage by more than 30%.
“With pork prices the lowest they’ve been in more than a decade, we’ve focused our marketing efforts on promoting pork as a great value for consumers,” Hy-Vee assistant VP meat operations Kenan Judge said in a statement. “Today’s shopper is looking for nutritious, economical meal ideas, and pork perfectly fits the bill.”
Patients prefer new diabetes drug Victoza over its competitor, survey finds
MONTREAL A new diabetes drug satisfied patients more than its competitor, according to a study funded by the drug’s manufacturer.
According to data on 379 patients who took the Diabetes Treatment Satisfaction Questionnaires, presented Thursday at the 20th World Diabetes Congress and published in medical journal The Lancet, patients taking Novo Nordisk’s drug Victoza (liraglutide) perceived less abnormally low or high blood sugar levels — known respectively as hypoglycemia and hyperglycemia — than those taking Byetta (exenatide), made by Eli Lilly & Co., Amylin Corp. and Alkermes.
Victoza is approved in Europe, but Novo Nordisk is still waiting for approval from the Food and Drug Administration in the United States.
“Liraglutide has shown here in a convincing study that it is associated with less nausea, less perceived hypoglycemia and definitely higher patient satisfaction compared to exenatide,” principal investigator Wolfgang Schmidt said in a statement. “Patient-reported outcomes data is an important extension of the efficacy data. If a patient is satisfied with his or her treatment, then they are much more likely to really stick to the treatment over the long term, which is necessary in Type 2 diabetes.”